Levcromakalim Eye Drop Formulation for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cromakalim, despite its strong biological activity, is poorly soluble in water and unsuitable for topical ocular administration due to insolubility issues, which has hindered its use for treating conditions like glaucoma.
Innovation Solution
A stable topical formulation of levcromakalim is developed, using specific excipient combinations that enhance solubility and stability, allowing effective ocular delivery without the need for covalent prodrugs or high levels of toxic components, maintaining a shelf life of at least 4 months.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cromakalim is used for topical ocular administration, then strong biological activity is achieved, but poor solubility in water prevents effective delivery
Solution Approach 1:
The patent uses DMSO as an intermediary solvent to dissolve cromakalim, which is then mixed with aqueous buffer to create a stable formulation. The DMSO acts as a bridge between the hydrophobic drug and the hydrophilic ocular environment, enabling effective delivery while maintaining solubility
Solution Approach 2:
The patent changes the physical-chemical parameters of the formulation by using co-solvents (DMSO, ethanol) and adjusting pH levels to optimize cromakalim solubility. The formulation maintains stability across different pH conditions while preserving drug activity
2Quantity of substance
If DMSO is used as a co-solvent to improve solubility, then cromakalim becomes soluble, but high percentage of DMSO is required which may be toxic
Solution Approach 1:
The patent optimizes the DMSO concentration to the minimum effective level (0.1-10%, preferably 0.5-5%) while maintaining cromakalim solubility and formulation stability. This parameter optimization reduces toxic exposure while preserving therapeutic efficacy
Solution Approach 2:
The formulation uses a composite solvent system combining DMSO with aqueous buffer, ethanol, and surfactants (polysorbate 80, cremophor). This composite approach distributes the solubility function across multiple components, reducing reliance on high DMSO concentrations
3Ease of operation
If cromakalim is formulated in aqueous buffer, then it can be administered topically, but it crystallizes or precipitates from solution
Solution Approach 1:
DMSO serves as a stabilizing intermediary that prevents cromakalim crystallization in aqueous environments. The patent maintains specific DMSO concentrations to ensure the drug remains in solution throughout storage and administration
Solution Approach 2:
The patent uses ethanol as an alternative co-solvent system that can also maintain cromakalim solubility and stability. This provides a backup formulation approach that copies the stabilizing effect of DMSO through a different chemical mechanism
4Productivity
If prodrugs or polymeric delivery systems are used to improve solubility, then delivery efficiency increases, but formulation complexity increases
Solution Approach 1:
The patent uses simple, well-characterized co-solvents (DMSO, ethanol) and surfactants that are readily available and easy to handle. These formulations can be prepared without complex equipment or specialized manufacturing processes, reducing overall system complexity
Solution Approach 2:
The patent achieves improved delivery through straightforward parameter adjustments (pH, co-solvent ratios, surfactant concentrations) rather than complex molecular modifications. This maintains formulation simplicity while enhancing delivery efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively lowers intraocular pressure and treats glaucoma, including normal tension glaucoma, with a benign toxicology profile and stable efficacy over 14 days, targeting the reduction of episcleral venous pressure to maximize IOP lowering.
Implementation Method 1
specific excipient combinations that enhance solubility
Implementation Method 2
The formulation effectively lowers intraocular pressure
Implementation Method 3
Cromakalim is soluble in highly polar 'universal' organic solvents such as DMSO (dimethyl sulfoxide), DMF (dimethyl formamide) or NMP (1-methylpyrrolidone) which are capable of hydrogen bonding interactions
Implementation Method 4
Cromakalim is soluble in highly polar 'universal' organic solvents such as DMSO (dimethyl sulfoxide), DMF (dimethyl formamide) or NMP (1-methylpyrrolidone) which are capable of hydrogen bonding interactions and hydrophobic interactions
Data Source
AI summary
An aqueous clear topical ocular solution of levcromakalim, or a pharmaceutically acceptable salt thereof, is provided in an effective therapeutic amount to treat the anterior portion of the human eye without the use of a covalent prodrug approach, a polymeric delivery system or a high level of toxic components, and with at least 4 months of shelf life stability, through the use of specifically discovered combinations of excipient components.